These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Products in the U.S. pipeline. Pharmaceutical Manufacturers Association. Biotechnology (N Y); 1991 Oct; 9(10):947-9. PubMed ID: 1367805 [No Abstract] [Full Text] [Related]
4. Upon closer inspection. As the U.S. imports more drugs and devices, the FDA's overseas initiatives aim to head off trouble at the source. Rhea S Mod Healthc; 2009 Mar; 39(13):28-30. PubMed ID: 19405431 [No Abstract] [Full Text] [Related]
5. New drugs: the AMA and the FDA. Appel JZ Ann Allergy; 1966 Jul; 24(7):333-6. PubMed ID: 5941864 [No Abstract] [Full Text] [Related]
6. New drugs and the Kefauver-Harris amendment. Krantz JC J New Drugs; 1966; 6(2):77-9. PubMed ID: 5917906 [No Abstract] [Full Text] [Related]
7. Issues in bringing new drugs to the market. Tracey WR Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329172 [No Abstract] [Full Text] [Related]
9. New drugs and product approvals from 2000. Taylor SE; Gage TW Tex Dent J; 2001 Nov; 118(11):1070-81. PubMed ID: 11806330 [No Abstract] [Full Text] [Related]
10. The year's new drugs. Rodman MJ RN; 1979 Jan; 42(1):33-46. PubMed ID: 252135 [No Abstract] [Full Text] [Related]
11. International research agreement leads to new U.S. guidelines. Maloney DM Hum Res Rep; 1995 Apr; 10(4):1-2. PubMed ID: 11654182 [No Abstract] [Full Text] [Related]
12. The evolution of new drug legislation. Kelsey FO BMQ; 1966 Sep; 17(3):72-81. PubMed ID: 5978212 [No Abstract] [Full Text] [Related]
13. When drugs are in short supply. Zurlinden J Nurs Spectr (Wash D C); 1999 Feb; 9(4):15-6. PubMed ID: 10542818 [No Abstract] [Full Text] [Related]
14. What's our pharmacologic readiness against a bioterrorism attack? Bucci KK; Briscoe-Dwyer L JAAPA; 2002 Apr; 15(4):10, 13. PubMed ID: 12012583 [No Abstract] [Full Text] [Related]
15. Problems relating to investigational drugs. Kelsey O Pharmakotherapia; 1964; 2(1):208-12. PubMed ID: 5875715 [No Abstract] [Full Text] [Related]
16. Drugs of limited commercial value. Van Woert MH N Engl J Med; 1980 Jul; 303(2):114. PubMed ID: 7383068 [No Abstract] [Full Text] [Related]
17. Biopharmaceutic equivalency and the role of the Food & Drug Administration. Hodges RM Am J Hosp Pharm; 1968 Mar; 25(3):121-7. PubMed ID: 5658859 [No Abstract] [Full Text] [Related]
18. Preparation and use of drug master files in the pharmaceutical industry. Personeus GR; Ascione P J Parenter Sci Technol; 1981; 35(2):63-9. PubMed ID: 7229835 [No Abstract] [Full Text] [Related]
19. U.S. study of drug effectiveness could bring new drug recalls. Bowles GC Mod Hosp; 1966 Aug; 107(2):128. PubMed ID: 5952736 [No Abstract] [Full Text] [Related]
20. New York State and drug lists: a history of confusion. Stetler CJ Med Mark Media; 1978 Sep; 13(9):36, 38, 40 passim. PubMed ID: 10316687 [No Abstract] [Full Text] [Related] [Next] [New Search]